



# Electronic Information Disclosure Statement



## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:   
10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket  
Number: CV01379K

Group Art  
Unit: 1617

Examiner: WILLIS, MICHAEL A

( 5567439 or 5576014 or 5587172 or 5587180 or 5591456 or 5593971 or 5595761 or 5607697 or  
5612353 or 5612367 or 5612378 or 5618707 or 5622719 or 5622985 or 5624920 or 5627176 or  
5631023 or 5631365 or 5633246 or 5635210 or 5639475 or 5639739 or 5656624 or 5661145 or  
search string: 5674893 or 5688785 or 5688787 or 5688990 or 5691375 or 5698527 or 5698548 or 5703234 or  
5709886 or 5718388 or 5728827 or 5734077 or 5739321 or 5744467 or 5747001 or 5753254 or  
5756470 or 5759865 or 5767115 or 5776491 or 5807576 or 5807577 or 5807578 or 5807834 or  
5808056 or 5817806 ).pn.

### US Patent Documents

**Note: Applicant is not required to submit a paper copy of cited US Patent Documents**

init	Citation	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	----------	---------------	------	----------	----------	-------	----------

No.					
SW P01	5567439	1996-10-22		Myers	
P02	5576014	1996-11-19		Mizumoto	
P03	5587172	1996-12-24		Cherukuri	
P04	5587180	1996-12-24		Allen	
P05	5591456	1997-01-07		Franson	
P06	5593971	1997-01-14		Tschollar	
P07	5595761	1997-01-21		Allen	
P08	5607697	1997-03-04		Alkire	
P09	5612353	1997-03-18		Ewing	
P10	5612367	1997-03-18		Timko	
P11	5612378	1997-03-18		Tianbao	
P12	5618707	1997-04-08		Homann	
P13	5622719	1997-04-22		Myers	
P14	5622985	1997-04-22		Olukotun	
P15	5624920	1997-04-29		McKittrick	
P16	5627176	1997-05-06		Kirkup	
P17	5631023	1997-05-20		Kearney	
P18	5631365	1997-05-20		Rosenblum	
P19	5633246	1997-05-27		McKittrick	
P20	5635210	1997-06-03		Allen	
P21	5639475	1997-06-17		Bettman	
P22	5639739	1997-06-17		Dominguez	
P23	5656624	1997-08-12		Vaccaro	
P24	5661145	1997-08-26		Davis	
P25	5674893	1997-10-07		Behounek	
P26	5688785	1997-11-18		Vaccaro	
P27	5688787	1997-11-18		Burnett	
SW P28	5688990	1997-11-18		Shankar	



<i>SM</i>	P29	5691375	1997-11-25		Behounek
	P30	5698527	1997-12-16		Kim
	P31	5698548	1997-12-16		Dugar
	P32	5703234	1997-12-30		Iwasaki
	P33	5709886	1998-01-20		Bettman
	P34	5718388	1998-02-17		Czekai
	P35	5728827	1998-03-17		Kannapan
	P36	5734077	1998-03-31		Regnier
	P37	5739321	1998-04-14		Wu
	P38	5744467	1998-04-28		McKittrick
	P39	5747001	1998-05-05		Wiedmann
	P40	5753254	1998-05-19		Khan
	P41	5756470	1998-05-26		Yumibe
	P42	5759865	1998-06-02		Bruns
	P43	5767115	1998-06-16		Rosenblum
	P44	5776491	1998-07-07		Allen
	P45	5807576	1998-09-15		Allen
	P46	5807577	1998-09-15		Ouali
	P47	5807578	1998-09-15		Acosta-Cuello
	P48	5807834	1998-09-15		Morehouse
	P49	5808056	1998-09-15		Amato
<i>SM</i>	P50	5817806	1998-10-06		Rossi

## Signature


Examiner Name	Date
<i>S. V. a</i>	<i>11/06/03</i>



# Electronic Information Disclosure Statement



## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:   
10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket  
Number: CV01379K



Group Art Unit: 1617







Examiner: WILLIS, MICHAEL A

search string: (6262042 or 6262047 or 6262098 or 6242605 or 6277584 or 6316029 or RE37721 or H0001286 ).pn.


### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents



init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
<i>Sw</i>	P01	6262042	2001-07-17		Cook		
<i>Sw</i>	P02	6262047	2001-07-17		Zhu		

SL	P03	6262098	2001-07-17		Huebner
SL	P04	6242605	2001-06-05		Raveendranath
SL	P05	6277584	2001-08-21		Chu
SL	P06	6316029	2001-11-13		Jain
SL	P07	RE37721	2002-05-28		Rosenblum
SL	P08	H0001286	1994-02-01		Eisman


## Signature

Examiner Name	Date
	11/06/03

# Electronic Information Disclosure Statement



## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:   
10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket  
Number: CV01379K

Group Art  
Unit: 1617



















Examiner: WILLIS, MICHAEL A

( 5827536 or 5827541 or 5831091 or 5843984 or 5846966 or 5847008 or 5847115 or 5851553 or  
5856473 or 5858409 or 5859051 or 5862999 or 5866163 or 5869098 or 5871781 or 5880148 or  
5883109 or 5886171 or 5919672 or 5925333 or 5952003 or 5952321 or 5959123 or 5972389 or  
search string: 5976570 or 5985936 or 5990102 or 5998441 or 6027747 or 6043257 or 6056975 or 6057342 or  
6063764 or 6066653 or 6071899 or 6074670 or 6080767 or 6080778 or 6084082 or 6090830 or  
6090839 or 6093812 or 6096883 or 6099865 or 6103705 or 6110493 or 6117429 or 6133001 or  
6139873 or 6143885 ).pn.

### US Patent Documents

**Note: Applicant is not required to submit a paper copy of cited US Patent Documents**

init	Citation	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	----------	---------------	------	----------	----------	-------	----------

	No.						
SW	P01	5827536	1998-10-27		Laruelle		
	P02	5827541	1998-10-27		Yarwood		
	P03	5831091	1998-11-03		Ohmizu		
	P04	5843984	1998-12-01		Clay		
	P05	5846966	1998-12-08		Rosenblum		
	P06	5847008	1998-12-08		Doebber		
	P07	5847115	1998-12-08		Iwasaki		
	P08	5851553	1998-12-22		Myers		
	P09	5856473	1999-01-05		Shankar		
	P10	5858409	1999-01-12		Karetny		
	P11	5859051	1999-01-12		Adams		
	P12	5862999	1999-01-26		Czekai		
	P13	5866163	1999-02-02		Myers		
	P14	5869098	1999-02-09		Misra		
	P15	5871781	1999-02-16		Myers		
	P16	5880148	1999-03-09		Edgar		
	P17	5883109	1999-03-16		Gregg		
SW	P18	5886171	1999-03-23		Wu		
			1999-07-				



50	P19	5919672	06		Homann
	P20	5925333	1999-07-20		Krieger
	P21	5952003	1999-09-14		Guentensberger
	P22	5952321	1999-09-14		Doherty
	P23	5959123	1999-09-28		Singh
	P24	5972389	1999-10-26		Shell
	P25	5976570	1999-11-02		Greaves
	P26	5985936	1999-11-16		Novak
	P27	5990102	1999-11-23		Hickey
	P28	5998441	1999-12-07		Palkowitz
	P29	6027747	2000-02-22		Terracol
	P30	6043257	2000-03-28		Dominguez
	P31	6056975	2000-05-02		Mitra
	P32	6057342	2000-05-02		Fevig
	P33	6063764	2000-05-16		Creasey
	P34	6066653	2000-05-23		Gregg
	P35	6071899	2000-06-06		Hickey
	P36	6074670	2000-06-13		Stamm
50	P37	6080767	2000-06-27		Klein
			2000-06-		

SL	P38	6080778	27		Yankner
	P39	6084082	2000-07-04		Ravikumar
	P40	6090830	2000-07-18		Myers
	P41	6090839	2000-07-18		Adams
	P42	6093812	2000-07-25		Thiruvengadam
	P43	6096883	2000-08-01		Wu
	P44	6099865	2000-08-08		Augello
	P45	6103705	2000-08-15		Uzan
	P46	6110493	2000-08-29		Guentensberger
	P47	6117429	2000-09-12		Bucci
	P48	6133001	2000-10-17		Homann
	P49	6139873	2000-10-31		Hughes
SL	P50	6143885	2000-11-07		Choi

## Signature

Examiner Name	Date
S. V. S.	11/06/03

# Electronic Information Disclosure Statement



RECEIVED  
AUG 27 2002  
TECH CENTER 1900126000

## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:   
10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket  
Number: CV01379K

Group Art  
Unit: 1617





























Examiner: WILLIS, MICHAEL A

( 2809194 or 3108097 or 3152173 or 3267104 or 3399192 or 3692895 or 4148923 or 4239763 or  
4567195 or 4626549 or 4654362 or 4680289 or 4937267 or 5093365 or 5106833 or 5110730 or  
5120713 or 5278176 or 5358852 or 5385885 or 5703188 or 5994554 or 6008237 or 6028109 or  
search string: 6033656 or 6040147 or 6121319 or 6127424 or 6140354 or 6147090 or 6147109 or 6147250 or  
6159997 or 6162805 or 6166049 or 6174665 or 6180138 or 6180625 or 6180660 or 6191117 or  
6191159 or 6200998 or 6207697 or 6207699 or 6207822 or 6214831 or 6235706 or 6245743 or  
6248781 or 6251852 ).pn.

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	----------	---------------	------	----------	----------	-------	----------

No.					
<i>gmo</i> P01	2809194	1957-10-08		Novello	
P02	3108097	1963-10-22		Ugi	
P03	3152173	1964-10-06		Ehrhart	
P04	3267104	1966-08-16		Hermans	
P05	3399192	1968-08-27		Regnier	
P06	3692895	1972-09-19		Nelson	
P07	4148923	1979-04-10		Giudicelli	
P08	4239763	1980-12-16		Milavec	
P09	4567195	1986-01-28		Schwarz	
P10	4626549	1986-12-02		Molloy	
P11	4654362	1987-03-31		Lommen	
P12	4680289	1987-07-14		Applezweig	
P13	4937267	1990-06-26		Holloway	
P14	5093365	1992-03-03		Berge	
P15	5106833	1992-04-21		Broze	
P16	5110730	1992-05-05		Edgington	
P17	5120713	1992-06-09		Mugica	
P18	5278176	1994-01-11		Lin	
P19	5358852	1994-10-25		Wu	
P20	5385885	1995-01-31		Gasic	
P21	5703188	1997-12-30		Mandeville	
P22	5994554	1999-11-30		Kliewer	
P23	6008237	1999-12-28		Sahoo	
P24	6028109	2000-02-22		Wilson	
P25	6033656	2000-03-07		Mikami	
P26	6040147	2000-03-21		Ridker	
P27	6121319	2000-09-19		Somers	
<i>gmo</i> P28	6127424	2000-10-03		Martin	

<i>g</i>	P29	6140354	2000-10-31		Dax
	P30	6147090	2000-11-14		DeNinno
	P31	6147109	2000-11-14		Liao
	P32	6147250	2000-11-14		Somers
	P33	6159997	2000-12-12		Tsujita
	P34	6162805	2000-12-19		Hefti
	P35	6166049	2000-12-26		Smith
	P36	6174665	2001-01-16		Dullien
	P37	6180138	2001-01-30		Engh
	P38	6180625	2001-01-30		Persson
	P39	6180660	2001-01-30		Whitney
	P40	6191117	2001-02-20		Kozachuk
	P41	6191159	2001-02-20		Pinto
	P42	6200998	2001-03-13		Sahoo
	P43	6207697	2001-03-27		Han
	P44	6207699	2001-03-27		Rothman
	P45	6207822	2001-03-27		Thiruvengadam
	P46	6214831	2001-04-10		Yokoo
	P47	6235706	2001-05-22		Gould
	P48	6245743	2001-06-12		Marlowe
	P49	6248781	2001-06-19		Jeppesen
<i>g</i>	P50	6251852	2001-06-26		Gould

## Signature

Examiner Name	Date
<i>S. W. S.</i>	<i>11/06/03</i>

--	--



E.O. 12812-1 TO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01379K

SERIAL NO.:

10/057,646

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis et al.

FILING DATE:

January 25, 2002

GROUP:

1614

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL					
	AM					
	AN					
	AO					
	AP					


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

54	AQ	Luis Gruberg, MD, Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia, American Heart Association Scientific Sessions 2000
	AR	
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTOL 1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01379K	SERIAL NO.: 10/057,646
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		APPLICANT: Harry R. Davis et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS



*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	FQ	US2003/0013729	01/16/03	Iqbal, et al.	514	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
52	FR	WO 96/19450	06/27/96	PCT	C07D	205/08		
	FS	WO 97/21676	06/19/97	PCT	C07D	205/09		
	FT	WO 97/41098	11/06/97	PCT	C07D	205/09		
	FU	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FV	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FW	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FX	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FY	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FZ	WO 00/28981	05/25/00	PCT	A61K	31/00		
	GA	WO 00/31548	06/02/00	PCT	G01N	33/68		
	GB	WO 00/32189	06/08/00	PCT	A61K	31/415		
	GC	WO 00/34240	06/15/00	PCT	C07D	205/08		
	GD	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GE	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
	GF	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GG	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GH	WO 00/38723	07/06/00	PCT	A61K	45/06		
	GI	WO 00/38724	07/06/00	PCT	A61K	45/06		
	GJ	WO 00/38725 /	07/06/00	PCT	A61K	45/06		
	GK	WO 00/38726	07/06/00	PCT	A61K	45/06		
	GL	WO 00/38727	07/06/00	PCT	A61K	45/06		
	GM	WO 00/38728	07/06/00	PCT	A61K	45/06		
	GN	WO 00/38729	07/06/00	PCT	A61K	45/06		
	GO	WO 00/40247	07/13/00	PCT	C07D	265/26		
	GP	WO 00/45817	08/10/00	PCT	A61K	31/505		
	GQ	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)	
	GR	WO 00/53149	09/14/00	PCT	A61K			
	GS	WO 00/53173	09/14/00	PCT	A61K	31/22		
	GT	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)	
	GU	WO 00/56403	09/28/00	PCT	A61P	9/10		
GV	WO 00/57859	10/05/00	PCT	A61K	9/48			
GW	WO 00/57918	10/05/00	PCT	A61K	47/44			
GX	WO 00/60107	10/12/00	PCT	C12P	17/10			
GY	WO 00/63153	10/26/00	PCT	C07C	69/734			
GZ	WO 00/63161	10/26/00	PCT	C07C	237/30			
HA	WO 00/63190	10/26/00	PCT	C07D	265/38			
HB	WO 00/63196	10/26/00	PCT	C07D	277/04			
HC	WO 00/63209	10/26/00	PCT	C07D	471/04			
HD	WO 00/63703	10/26/00	PCT	G01N	33/92			

RECEIVED  
APR 6 2003  
FBI/DOJ  
FBI/DOJ  
FBI/DOJ






FORM PTO-1019

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANTATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646APPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

56	HE	WO 00/69412	11/23/00	PCT	A61K	9/127		
	HF	WO 00/69445	11/23/00	PCT	A61K	31/785		
	HG	WO 00/72825	12/7/00	PCT	A61K	9/14		
	HH	WO 00/72829	12/07/00	PCT	A61K	9/48		
	HI	WO 00/75103	12/14/00	PCT	C07C	235/60	X(abs.)	
	HJ	WO 00/76482	12/21/00	PCT	A61K	9/48		
	HK	WO 00/76488	12/21/00	PCT	A61K	31/00		
	HL	WO 00/78312	12/28/00	PCT	A61K	31/421		
	HM	WO 00/78313	12/28/00	PCT	A61K	31/422		
	HN	WO 01/00579	01/04/01	PCT	C07D	213/65		
	HO	WO 01/00603	01/04/01	PCT	C07D	277/24		
	HP	WO 01/08686	02/08/01	PCT	A61K	31/495		
	HQ	WO 01/12176	02/22/01	PCT	A61K	31/16		
	HR	WO 01/12187	02/22/01	PCT	A61K	31/404		
	HS	WO 01/12612	02/22/01	PCT	C07D	257/04		
	HT	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)	
	HU	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)	
	HV	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)	
	HW	WO 01/15744	03/08/01	PCT	A61K	49/00		
	HX	WO 01/16120	03/08/01	PCT	C07D	263/32		
	HY	WO 01/17994	03/15/01	PCT	C07D	413/12		
	HZ	WO 01/18210	03/15/01	PCT	C12N	15/12		
	IA	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)	
	IB	WO 01/21259	03/29/01	PCT	A61P			
	IC	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)	
	ID	WO 01/21647	03/29/01	PCT	C07K	14/00		
	IE	WO 01/22962	04/05/01	PCT	A61K	31/435		
	IF	WO 01/25225	04/12/01	PCT	C07D	317/18		
	IG	WO 01/25226	04/12/01	PCT	C07D	327/04		
	IH	WO 01/30343	05/03/01	PCT	A61K	31/40		
	II	WO 01/32161	05/10/01	PCT	A61K	31/00		
	IJ	WO 01/35970	05/25/01	PCT	A61K	35/76		
	IK	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)	
	IL	WO 01/45676	06/28/01	PCT	A61K	9/24		
	IM	WO 01/49267	07/12/01	PCT	A61K	9/14		
	IN	WO 01/64221	09/07/01	PCT	A61K	31/52		
	IO	WO 01/76632	10/18/01	PCT	A61K	45/06		
	IP	WO 02/50090	06/27/02	PCT	C07H	15/26		
	IQ	WO 02/058696	08/01/02	PCT	A61K	31/397		
	IR	WO 02/058731	08/01/02	PCT	A61K	45/06		
	IS	WO 02/058732	08/01/02	PCT	A61K	45/06		
	IT	WO 02/058733	08/01/02	PCT	A61K	45/06		
	IU	WO 02/058734	08/01/02	PCT	A61K	45/06		
	IV	WO 02/058685	08/01/02	PCT	A61K	31/00		
	IW	WO 02/064130	08/22/02	PCT	A61K	31/195		
	IX	WO 02/064549	08/22/02	PCT	C07C	275/34		
57	IY	WO 02/064664	08/22/02	PCT	C08G	77/02		



Sheet

3

of

TECH CATER 1600200

APR 15 2003

RECEIVED

FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,846INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614500

(Use several sheets if necessary)

5	IZ	WO 02/072104	09/19/02	PCT	A61K	31/54		
	JA	WO 02/081454	10/17/02	PCT	C07D	239/36		
	JB	WO 02/26729	04/04/02	PCT	C07D	311/66		
	JC	WO 02/064094	08/22/02	PCT	A61K			
	JD	WO 03/018024	03/06/03	PCT	A61K	31/55		
5	JE	WO 03/018059	03/06/03	PCT	A61K	45/06		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

5	JF	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic &amp; Medicinal Chemistry Ltrs., Oxford, G.B., 8:313-318</i> (1998)
	JG	Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic &amp; Medicinal Chem. Ltrs. Oxford, G.B. 8:319-322</i> (1998)
	JH	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)
	JI	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylidenaniline", <i>Chemical Abstracts No. 15, 86</i> (April 11, 1997)
	JJ	Otto et al., "Stereochemistry of dehydration and halogenation of $\alpha R^*$ and $\alpha S^*$ isomeric 3-( $\alpha$ -hydroxybenzyl)-1,4 diphenyl-2 azetidinones, <i>Chemical Abstracts No. 19, 99</i> (Nov. 7, 1983)
	JK	T. Durst et al., "Metallation of N-Substituted $\beta$ -Lactams. A Method of the Introduction of 3-substituents into $\beta$ -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)
	JL	Nobuki, O. et al., "Stereoselective syntheses of $\beta$ -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106, 17</i> (April 27, 1987)
	JM	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy- and 4-Hydroxy-5-oxohexanoic Acid $\gamma$ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-924 (1982)
	JN	H. Otto et al. "Darstellung und Stereochemie von 3-( $\alpha$ -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)
	JO	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)
	JP	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)
	JQ	Panfil, I. et al. "Synthesis of $\beta$ -Lactams from $\alpha$ , $\beta$ -Unsaturated Sugar $\delta$ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)
	JR	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63:71 (1988)
	JS	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)
	JT	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B <i>Indian J. Chem.</i> 1134-37 (1990)
	JU	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)
	JV	Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)
	JW	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)
5	JX	Summary Factfile, "Anti-Atherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)



FORM PTO-449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:

SERIAL NO.:

CV01379K

10/057646

APPLICANT:

Harry R. Davis et al.



FILING DATE:

January 25, 2002

GROUP:

1614

5	JY	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin $\beta$ -tigogenin cellobioside (CP-88818; $\beta$ -tigue side) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)
	JZ	Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)
	KA	Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)
	KB	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)
	KC	Vaccaro, W, et al, "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. &amp; Med. Chem.</i> 6:1429-1437 (1998)
	KD	G. Wu et al, "A Novel One-Step Diastereo-and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).
	KE	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)
	KF	Abbott et al, "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.
	KG	M. Feher et al., 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).
	KH	M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 441-443 (2001)
	KI	C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41:1 70-78 (Jan. 2001)
	KJ	W. Oppolzer et al., "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).
	KK	M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)
	KL	M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal effects", 159 <i>Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)
	KM	I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).
	KN	A. Andersson et al., "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", 1 <i>European Heart. J. Supplements</i> S80 - S90 (1999)
	KO	H. Gylling et al, "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)
	KP	T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)
	KQ	T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)
5	KR	M. Van Heek et al., "In Vivo Metabolism - Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)

Sheet 5 of 9


FORM PTO-49

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT  
BY APPLICANTATTY. DOCKET NO.:  
CV01379K  
APPLICANT:  
Harry R. Davis et al.SERIAL NO.  
10/057,646FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

5	KS	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," <i>151 Atherosclerosis</i> 1:133 (July 2000)
	KT	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", <i>10 Atherosclerosis</i> 2, 289-297 (1990)
	KU	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," <i>32 J.Lipid Res.</i> 1941-1948 (1991)
	KV	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," <i>45 Metabolism</i> 6 673-679 (June 1996)
	KW	M. Huettinger <i>et al.</i> , "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).
	KX	J. Best <i>et al.</i> , "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)
	KY	P. Chong, <i>et al.</i> , "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)
	KZ	M. Brown <i>et al.</i> , "A Receptor - Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)
	LA	L. Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)
	LB	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 <sup>th</sup> Ed. 2001)
	LC	K. Fassbender <i>et al.</i> , "Simvastatin Strongly Reduces Levels of Alzheimer's Disease $\beta$ -Amyloid Peptides A $\beta$ 42 and A $\beta$ 40 in vitro and in vivo", <i>PNAs Early Edition</i> , <a href="http://www.phas.org/cgi/doi/10.1073/phas.081620098">www.phas.org/cgi/doi/10.1073/phas.081620098</a> (2001)
	LD	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)
	LE	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001
	LF	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001
	LG	Dementia and Statins", <i>The Lancet</i> March 17, 2001
	LH	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001
	LI	Cholesterol Drugs Ease Alzheimer's Damage; <a href="http://www.usatoday.com">www.usatoday.com</a> April 10, 2001
	LJ	Lovastatin XL of Use in Alzheimer's? News Edge (May 2, 2001)
	LK	L. Refolo <i>et al.</i> , "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, <i>Neurobiology of Disease</i> 321-331 (2000)
	LL	D. Kang <i>et al.</i> , "Modulation of Amyloid $\beta$ -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)
	LM	Y.A. Kesaniewmi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)
	LN	J. Busciglio <i>et al.</i> , "Generation of $\beta$ -amyloid in the secretory pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci, USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)
	LO	L. Farrer <i>et al.</i> , "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)
5	LP	A. Goate <i>et al.</i> , "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature</i> No. 6311, 704-706 (Feb. 21, 1991)

RECEIVED  
APR 16 2003  
TECH CENTER 1600-900



FORM PTO-1019

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

ATTY. DOCKET NO.:  
CV01379K

SERIAL NO.:  
10/057,646

APPLICANT:  
Harry R. Davis et al.



FILING DATE:  
January 25, 2002

GROUP:  
1614

(Use several sheets if necessary)

Sw	LQ	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> 169-179 (Feb. 1989)
	LR	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)
	LS	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)
	LT	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)
	LU	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)
	LV	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)
	LW	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:805-815 (1992)
	LX	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959
	LY	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479
	LZ	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> , 312:1061-1065 (April 27, 1996)
	MA	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> ; 8:391-395 (1998)
	MB	L. Gruberb, 2000, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive protein (CRP) and Chlamydia", <i>American Heart Association Scientific Sessions</i>
	MC	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)
	MD	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 3-16
	ME	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313
	MF	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11
	MG	Remington 1995, "The Science and Practice of Pharmacy, (19 <sup>th</sup> Ed. 1995) p. 963
	MH	M. Chistie <i>et al.</i> , "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)
	MI	C. Janus <i>et al.</i> , "A $\beta$ Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)
	MJ	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)
	MK	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Bichem</i> ; 19:850 (1981)
	ML	Steele WG, <i>et al.</i> , "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> ; 1:98-101 (1976)
Sw	MM	Salen <i>et al.</i> , "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Choelsterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipd Res.</i> ; 30:1319-1330 (1989)

RECEIVED  
APR 16 2003  
CENTRAL FILE

Sheet 7

9

FORM PTO-449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

CV01379K

10/057,646

APPLICANT:

Harry R. Davis et al.

FILING DATE:

January 25, 2002


GROUP:


1614

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

SN	MN	Lutjohann <i>et al.</i> , "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> <b>36:8</b> ; 1763-1773 (1995)
	MO	Zhang <i>et al.</i> , "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of $\gamma$ - Secretase" <b>274 J. Biol. Chem.</b> , 13:8966-8972 (1999)
	MP	Zhang <i>et al.</i> , "Biochemical Characterization of the $\gamma$ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> <b>40:5049-5055</b> (2001)
	MQ	Ida <i>et al.</i> , "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", <b>271 J. Biol. Chem.</b> ; 37:22908-22914 (1996)
	MR	Lichtlen, P.R. <i>et al.</i> , 1990, <i>Lancet</i> ; <b>335:1109-1113</b>
	MS	Bays <i>et al.</i> , "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , <b>23:1209-1230</b> (2001)
	MT	E. Leitersdorf <i>et al.</i> , "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , <b>3:E17-E23</b> (June 2001)
	MU	Bauer <i>et al.</i> , "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , <b>69:2 p5</b> (Mar. 6-10, 2001)
	MV	Keung <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , <b>69:2 p55</b> (Mar. 6-10, 2001)
	MW	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72<sup>nd</sup> EAS Congress</i> , p. 38 (May 21-23, 2001)
	MX	T. Kosoglou <i>et al.</i> , "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel, 72<sup>nd</sup> EAS Congress</i> , p. 89 (May 21-23, 2001)
	MY	L. Reyderman <i>et al.</i> , "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)
	MZ	P. Statkevich <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology &amp; Therapeutics</i> , <b>69:67</b> (March 6-10, 2001)
	NA	Knopp <i>et al.</i> , "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72<sup>nd</sup> EAS Congress</i> , p. 90 (May 21-23, 2001)
	NB	Kosoglou <i>et al.</i> , "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72<sup>nd</sup> EAS Congress</i> , p. 38 (March 6-10, 2001)
	NC	Bays <i>et al.</i> , "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>
	ND	Castaner <i>et al.</i> , "Ezetimibe - Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , <b>25(7):679-685</b> (2000)
	NE	Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>
SN	NE	Van Heek <i>et al.</i> , "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , <b>129:1748-1754</b> (2000)







FORM PTO-1449  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: CV01379K	SERIAL NO.: 10/057,646
APPLICANT: Harry R. Davis et al.	
FILING DATE: January 25, 2002	GROUP: 1614

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

32	NG	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>
	NH	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47<sup>th</sup> ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)</i>
	NI	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic &amp; Medicinal Chemistry</i> , 7:2199-2202 (1999)
	NJ	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)
	NK	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 8:313-318 (1998)
	NL	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)
	NM	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6<sup>th</sup> International Symposium on Global Risk of Coronary Heart Disease and Stroke - Abstract Book</i> , p. 35 (June 12-15, 2002)
	NN	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 <sup>th</sup> Annual Meeting of the EASD, September 1-5, 2002
	NO	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475
	NP	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248
	NQ	Burrier, R.E. <i>et al.</i> , 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:1545-1551
	NR	Burrier, R.E. <i>et al.</i> , 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163
	NS	E.F. Binder <i>et al.</i> , "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)
	NT	MR Haymart <i>et al.</i> , "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)
	NU	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)
	NV	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)
	NW	Van Heek <i>et al.</i> , "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)
	NX	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)
	NY	H. Hauser, <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998
	NZ	G. Salen, <i>et al.</i> , "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992
32	OA	Stedman's Medical Dictionary, 27 <sup>th</sup> Edition, pg. 1381

Sheet 9 of 9


FORM PTO-1249

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

SW	OB	P.F. Belamarich <i>et al.</i> , "Response to Diet and Cholestyramine in a Patient with Sitosterolemia", <i>Pediatrics</i> , 977-981, (December 1990)
SW	OC	G. Salen <i>et al.</i> , "Lethal Atherosclerosis Associated With Abnormal Plasma and Tissue Sterol Composition in Sitosterolemia With Xanthomatosis", <i>Journal of Lipid Research</i> , 1126-1133, (September 1985)
SW	OD	G.R. Thompson <i>et al.</i> , "Novel Lipid-Regulating Drugs, Exp. Opin. Invest. Drugs, 9(11):2619-2628, 2000
S. V. O		DATE CONSIDERED 11-06-03





FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.

(Use several sheets if necessary)

FILING DATE:  
January 25, 2002GROUP:  
1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
5	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
5	AE	US2002/0128252	09/12/02	Glombik et al.			
	AF	10/057,534	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AN	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
	AT	10/166,942	06/11/02	Anima Ghosal et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
5	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
	BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
5	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		



FORM PTG-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

SV	BV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs)	
	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
	CF	FR 1103113	10/31/55	FRANCE				X
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)	
	CH	GB 861367	02/22/61	GB	A61K			
	CI	GB 902658	08/09/62	GB	C07D			
	CJ	GB 1415295	11/26/75	GB	C07C	59/26		
	CK	GB 2329334 A	03/24/99	GB	A61K	45/00		
	CL	JP 028057	10/01/81	JAPAN			X(abs.)	
	CM	JP 121479	12/10/86	JAPAN			X(abs.)	
	CN	JP 136485	05/26/81	JAPAN			X(abs.)	
	CO	JP 180212	03/24/86	JAPAN			X(abs.)	
	CP	JP 219681	04/14/87	JAPAN			X(abs.)	
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
	CS	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)	
	CT	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)	
	CU	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)	
	CV	JP 4356195 A	1993	JAPAN			X(abs.)	
	CW	JP 4356495	12/10/92	JAPAN			X(abs.)	
	CX	JP 5058993 A	1993	JAPAN			X(abs.)	
	CY	JP 61280295 A	1987	JAPAN			X(abs.)	
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
	DD	WO 87/04429	07/30/87	PCT	C07D	205/08		
	DE	WO 88/04656	06/30/88	PCT	C07D	405/04		
	DF	WO 88/05296	07/28/88	PCT	A61K	31/365		
	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
	DH	WO 92/13837	08/20/92	PCT	C07D	205/085		
	DI	WO 93/02048	02/04/93	PCT	C07D	205/08		
	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00		
	DK	WO 93/11150	06/10/93	PCT	C07J	71/00		
	DL	WO 94/00480	01/06/94	PCT	C07J	71/00		
	DM	WO 94/14433	07/07/94	PCT	A61K	31/395		
	DN	WO 94/17038	08/04/94	PCT	C07D	205/12		
	DO	WO 94/20535	09/15/94	PCT	C07K	13/00		
	DP	WO 95/04533	02/16/95	PCT	A61K	31/445		
	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435		
	DR	WO 95/08532	03/30/95	PCT	C07D	205/08		
	DS	WO 95/18143	07/6/95	PCT	C07J	71/00		
SV	DT	WO 95/26334	10/05/95	PCT	C07D	205/08		

RECEIVED  
JAN 23 2003  
TECH CENTER 16002900



FORM RPTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
EH	WO 98/01100	01/15/98	PCT	A61K			
EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	

RECEIVED  
JAN 23 2003  
TECH CENTER 1600/2900

Sheet 4 of 4

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
CV01379KSERIAL NO.:  
10/057,646INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT:  
Harry R. Davis et al.FILING DATE:  
January 25, 2002GROUP:  
1614

(Use several sheets if necessary)

FO	WO 00/18395	04/06/00	PCT	A61K	31/215		
FP	WO 00/20623	04/13/00	PCT	C12P	41/00		
FQ	WO 00/23415	04/27/00	PCT	C07C	69/734		
FR	WO 00/23416	04/27/00	PCT	C07C	69/734		
FS	WO 00/23425	04/27/00	PCT	C07D	209/80		
FT	WO 00/23445	04/27/00	PCT	C07D	471/12		
FU	WO 00/23451	04/27/00	PCT	C07D	487/14		
FV	WO 00/28981	05/25/00	PCT	A61K	31/00		
FW	WO 00/31548	06/02/00	PCT	G01N	33/68		
FX	WO 00/32189	06/08/00	PCT	A61K	31/415		
FY	WO 00/34240	06/15/00	PCT	C07D	205/08		
FZ	WO 00/37057	06/29/00	PCT	A61K	9/48		
GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
GB	WO 00/38721	07/06/00	PCT	A61K	45/06		
GC	WO 00/38722	07/06/00	PCT	A61K	45/06		
GD	WO 00/38723	07/06/00	PCT	A61K	45/06		
GE	WO 00/38724	07/06/00	PCT	A61K	45/06		



DATE CONSIDERED

11/06/03

30608

RECEIVED  
JAN 23 2003  
TECH CENTER 1600/2900

# Electronic Information Disclosure Statement



## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:



10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket

CV01379K

Number:

Group Art

1617

Unit:

Examiner: WILLIS, MICHAEL A

search string: ( 3716583 or 3781328 or 3948973 or 4072705 or 4075000 or 4144232 or 4178695 or 4179515 or 4235896 or 4250191 or 4260743 or 4304718 or 4375475 or 4443372 or 4444784 or 4472309 or 4479900 or 4500456 or 4534786 or 4564609 or 4576748 or 4576749 or 4576753 or 4581170 or 4595532 or 4602003 or 4602005 or 4614614 or 4616047 or 4620867 or 4633017 or 4642903 or 4675399 or 4680391 or 4739101 or 4778883 or 4784734 or 4794108 or 4800079 or 4803266 or 4834846 or 4814354 or 4834846 or 4871752 or 4876365 or 4879301 or 4895726 or 4925672 or 4939248 or 4166907 or 20010028895 or 20020006919 ).pn.

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	----------	---------------	------	----------	----------	-------	----------





No.					
P01	3716583	1973-02-13		Nakamura	
P02	3781328	1973-12-25		Witte	
P03	3948973	1976-04-06		Phillips	
P04	4072705	1978-02-07		Mieville	
P05	4075000	1978-02-21		Abdulla	
P06	4144232	1979-03-13		Koppel	
P07	4178695	1979-12-18		Erbeia	
P08	4179515	1979-12-18		Mieville	
P09	4235896	1980-11-25		Mieville	
P10	4250191	1981-02-10		Edwards	
P11	4260743	1981-04-07		Bose	
P12	4304718	1981-12-08		Kamiya	
P13	4375475	1983-03-01		Willard	
P14	4443372	1984-04-17		Luo	
P15	4444784	1984-04-24		Hoffman	
P16	4472309	1984-09-18		Kamiya	
P17	4479900	1984-10-30		Luo	
P18	4500456	1985-02-19		Spitzer	
P19	4534786	1985-08-13		Luo	
P20	4564609	1986-01-14		Tamura	
P21	4576748	1986-03-18		Greenlee	
P22	4576749	1986-03-18		Zahler	
P23	4576753	1986-03-18		Kamiya	
P24	4581170	1986-04-08		Mueller	
P25	4595532	1986-06-17		Miller	
P26	4602003	1986-07-22		Malinow	
P27	4602005	1986-07-22		Malinow	
P28	4614614	1986-09-30		Ernest	

50	P29	4616047	1986-10-07		Lafon
1	P30	4620867	1986-11-04		Luo
	P31	4633017	1986-12-30		Mueller
	P32	4642903	1987-02-17		Davies
	P33	4675399	1987-06-23		Miller
	P34	4680391	1987-07-14		Firestone
	P35	4739101	1988-04-19		Bourgogne
	P36	4778883	1988-10-18		Yoshioka
	P37	4784734	1988-11-15		Torii
	P38	4794108	1988-12-27		Kishimoto
	P39	4800079	1989-01-24		Boyer
	P40	4803266	1989-02-07		Kawashima
	P41	4834846	1989-05-30		Abramson
	P42	4814354	1989-03-21		Ghebre-Sellassie
	P43	4834846	1989-05-30		Abramson
	P44	4871752	1989-10-03		Zermatter
	P45	4876365	1989-10-24		Kirkup
	P46	4879301	1989-11-07		Umio
	P47	4895726	1990-01-23		Curtet
	P48	4925672	1990-05-15		Gremm
	P49	4939248	1990-07-03		Yoshioka
50	P50	4166907	1979-09-04		Krapcho


## Published Applications

**Note: Applicant is not required to submit a paper copy of cited US Patent Documents**


init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	--------------	---------------	------	----------	----------	-------	----------

	U01	20010028895	2002-10-11		Bisgaier
	U02	20020006919	2002-01-17		Thosar

## Signature

Examiner Name	Date
	11/06/03





# Electronic Information Disclosure Statement

RECEIVED  
AUG 22 2002  
TECH CENTER 1500/2411

## COMBINATIONS OF NICOTINIC ACID AND DERIVATIVES THEREOF AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:



10/057646

Confirmation: 3480

Applicant(s): Harry Davis

Docket

CV01379K

Number:

Group Art

1617

Unit:

Examiner: WILLIS, MICHAEL A

( 4952689 or 4961890 or 4983597 or 4990535 or 5030628 or 5073374 or 5091525 or 5099034 or 5100675 or 5112616 or 5120729 or 5130333 or 5145684 or 5157025 or 5162117 or 5178878 or 5188825 or 5190970 or 5204461 or 5219574 or 5223264 or 5229362 or 5229381 or 5229510 or 5260305 or 5286631 or 5298497 or 5306817 or 5318767 or 5348953 or 5350868 or 5384124 or 5399363 or 5401513 or 5412092 or 5429824 or 5446464 or 5461039 or 5464632 or 5494683 or 5503846 or 5510118 or 5510466 or 5518187 or 5518738 or 5545628 or 5550229 or 5552160 or 5561227 or 5563264 ).pn.

search string:

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	----------	---------------	------	----------	----------	-------	----------


No.					
P01	4952689	1990-08-28		Kawashima	
P02	4961890	1990-10-09		Boyer	
P03	4983597	1991-01-08		Yang	
P04	4990535	1991-02-05		Cho	
P05	5030628	1991-07-09		Joyeau	
P06	5073374	1991-12-17		McCarty	
P07	5091525	1992-02-25		Brennan	
P08	5099034	1992-03-24		Yoshida	
P09	5100675	1992-03-31		Cho	
P10	5112616	1992-05-12		McCarty	
P11	5120729	1992-06-09		Chabala	
P12	5130333	1992-07-14		Pan	
P13	5145684	1992-09-08		Liversidge	
P14	5157025	1992-10-22		Aberg	
P15	5162117	1992-11-10		Stupak	
P16	5178878	1993-01-12		Wehling	
P17	5188825	1993-02-23		Iles	
P18	5190970	1993-03-02		Pan	
P19	5204461	1993-04-20		Murayama	
P20	5219574	1993-06-15		Wehling	
P21	5223264	1993-06-29		Wehling	
P22	5229362	1993-07-20		Kirst	
P23	5229381	1993-07-20		Doherty	
P24	5229510	1993-07-20		Knight	
P25	5260305	1993-11-09		Dennick	
P26	5286631	1994-02-15		Boeck	
P27	5298497	1994-03-29		Tschollar	
P28	5306817	1994-04-26		Thiruvengadam	

52	P29	5318767	1994-06-07		Liversidge
	P30	5348953	1994-09-20		Doherty
	P31	5350868	1994-09-27		Yoshida
	P32	5384124	1995-01-24		Courteille
	P33	5399363	1995-03-21		Liversidge
	P34	5401513	1995-03-28		Wehling
	P35	5412092	1995-05-02		Rey
	P36	5429824	1995-07-04		June
	P37	5446464	1995-08-29		Feldle
	P38	5461039	1995-10-24		Tschollar
	P39	5464632	1995-11-07		Cousin
	P40	5494683	1996-02-27		Liversidge
	P41	5503846	1996-04-02		Wehling
	P42	5510118	1996-04-23		Bosch
	P43	5510466	1996-04-23		Krieger
	P44	5518187	1996-05-21		Bruno
	P45	5518738	1996-05-21		Eickhoff
	P46	5545628	1996-08-13		Deboeck
	P47	5550229	1996-08-27		Iwasaki
	P48	5552160	1996-09-03		Liversidge
	P49	5561227	1996-10-01		Thiruvengadam
52	P50	5563264	1996-10-08		Kume

## Signature

Examiner Name	Date
S. ✓ d	11/06/03

--	--

MAY 06 2003  
TECH CENTER 1600/2900Sheet 1 of 1

FORM PTO-147 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	ATTY. DOCKET NO.: <b>CV01379K</b>	SERIAL NO.: <b>10/057,646</b>
	APPLICANT: <b>Harry R. Davis, et al.</b>	
	FILING DATE: <b>January 25, 2002</b>	GROUP: <b>1614</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<u>SW</u>	AA	<b>Exhibit A:</b> SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
<u>SW</u>	AB	<b>Exhibit B:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AC	<b>Exhibit C:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AD	<b>Exhibit D:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AE	<b>Exhibit E:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AF	<b>Exhibit F:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AG	<b>Exhibit G:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AH	<b>Exhibit H:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AI	<b>Exhibit 1:</b> Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585
	AJ	<b>Exhibit 2:</b> Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112
	AK	<b>Exhibit 3:</b> Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566
	AL	<b>Exhibit 4:</b> Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130
<u>SW</u>	AM	<b>Exhibit 5:</b> Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8
EXAMINER <u>S. L. W.</u>		DATE CONSIDERED <u>10-26-03</u>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.